Large Scale Biology Corporation (LSBC) has started a research collaboration with Novozymes Biotech to apply LSBC's gene shuffling and molecular evolution technologies to genes of interest to Novozymes Biotech.
Under the collaboration, Novozymes Biotech will provide to LSBC genes encoding proteins of commercial interest and LSBC scientists will apply novel techniques in an attempt to modify the properties of the protein products.
LSBC claims that its proprietary molecular evolution technology, called Molecular GRAMMR, can achieve gene improvement via a different and more efficient approach than conventional gene shuffling methods.
"We are delighted to have a chance to work with Novozymes Biotech in a project of mutual interest," said John D. Fowler, LSBC's president. "Our goal is to add value to our clients' life sciences R&D programs by applying LSBC's unique collection of molecular biology and bioinformatics tools," he added.